Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.

2.50
Hdl Handle:
http://hdl.handle.net/10033/619049
Title:
Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.
Authors:
Akmatov, Manas K; Stumme, Melanie; Pessler, Frank
Abstract:
Methotrexate (MTX) is used at low doses to treat rheumatologic disorders in the paediatric age group. Toxicity is observed despite the low doses used. Even though recommendations for monitoring of early signs of toxicity exist in many countries, real-life practice may vary. We therefore assessed current practice in Germany, Switzerland and Austria.
Affiliation:
TWINCORE Centre for Experimental and Clinical Infection Research Feodor-Lynen-Str. 7 30625 Hannover, Germany.
Citation:
Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012., 34 (3):548-53 Clin. Exp. Rheumatol.
Journal:
Clinical and experimental rheumatology
Issue Date:
30-Aug-2016
URI:
http://hdl.handle.net/10033/619049
PubMed ID:
27156925
Type:
Article
Language:
en
ISSN:
0392-856X
Appears in Collections:
publications of the research group biomarker in infection and immunity [[TC] BIOM)

Full metadata record

DC FieldValue Language
dc.contributor.authorAkmatov, Manas Ken
dc.contributor.authorStumme, Melanieen
dc.contributor.authorPessler, Franken
dc.date.accessioned2016-08-30T15:08:52Z-
dc.date.available2016-08-30T15:08:52Z-
dc.date.issued2016-08-30-
dc.identifier.citationReal-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012., 34 (3):548-53 Clin. Exp. Rheumatol.en
dc.identifier.issn0392-856X-
dc.identifier.pmid27156925-
dc.identifier.urihttp://hdl.handle.net/10033/619049-
dc.description.abstractMethotrexate (MTX) is used at low doses to treat rheumatologic disorders in the paediatric age group. Toxicity is observed despite the low doses used. Even though recommendations for monitoring of early signs of toxicity exist in many countries, real-life practice may vary. We therefore assessed current practice in Germany, Switzerland and Austria.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAdolescenten
dc.subject.meshAntirheumatic Agentsen
dc.subject.meshArthritis, Juvenileen
dc.subject.meshAustriaen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshDrug Monitoringen
dc.subject.meshDrug-Related Side Effects and Adverse Reactionsen
dc.subject.meshFemaleen
dc.subject.meshGermanyen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMedication Therapy Managementen
dc.subject.meshMethotrexateen
dc.subject.meshSwitzerlanden
dc.subject.meshYoung Adulten
dc.titleReal-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.en
dc.typeArticleen
dc.contributor.departmentTWINCORE Centre for Experimental and Clinical Infection Research Feodor-Lynen-Str. 7 30625 Hannover, Germany.en
dc.identifier.journalClinical and experimental rheumatologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.